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Abstract
Inappropriate Hedgehog (Hh) signaling underlies development of a subset of medulloblastomas, and tumors with
elevated HH signaling activity express the stem cell self-renewal gene BMI1. To test whether Bmi1 is required for
Hh-driven medulloblastoma development, we varied Bmi1 gene dosage in transgenic mice expressing an onco-
genic Hh effector, SmoA1, driven by a glial fibrillary acidic protein (GFAP) promoter. Whereas 100% of SmoA1;
Bmi1+/+ or SmoA1;Bmi1+/− mice examined between postnatal (P) days 14 and 26 had typical medulloblastomas
(N = 29), tumors were not detected in any of the SmoA1;Bmi1−/− animals examined (N = 6). Instead, small ec-
topic collections of cells were present in the region of greatest tumor load in SmoA1 animals, suggesting that
medulloblastomas were initiated but failed to undergo expansion into frank tumors. Cells within these Bmi1−/−
lesions expressed SmoA1 but were largely nonproliferative, in contrast to cells in Bmi1+/+ tumors (6.2% vs
81.9% PCNA-positive, respectively). Ectopic cells were negative for the progenitor marker nestin, strongly
GFAP–positive, and highly apoptotic, relative to Bmi1+/+ tumor cells (29.6% vs 6.3% TUNEL-positive). The alter-
ations in proliferation and apoptosis in SmoA1;Bmi1−/− ectopic cells are associated with reduced levels of Cyclin
D1 and elevated expression of cyclin-dependent kinase inhibitor p19Arf, two inversely regulated downstream targets
of Bmi1. These data provide the first demonstration that Bmi1 is required for spontaneous de novo development of
a solid tumor arising in the brain, suggest a crucial role for Bmi1-dependent, nestin-expressing progenitor cells in
medulloblastoma expansion, and implicate Bmi1 as a key factor required for Hh pathway-driven tumorigenesis.
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Introduction
Medulloblastoma, a primitive neuroectodermal tumor of the cerebel-
lum, is the most common pediatric brain tumor, representing approx-
imately 20% of newly diagnosed CNS malignancies in children [1].
Oncogenic mutations in Hedgehog (Hh) pathway components have
been identified in up to 20% to 25% of human medulloblastomas [2],
and aberrant activation of the Hh pathway, measured by expression of
HH target genes, has been detected in a significantly higher percentage
of cases [3,4]. In normal cerebellum, the Hh pathway regulates prolif-
eration of granule neuron precursors (CGNPs), which are potential
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medulloblastoma progenitors that comprise the transient external gran-
ular layer (EGL) of the cerebellum [5]. During early postnatal develop-
ment, CGNPs become refractory to the Shh signal for proliferation,
withdraw from the cell cycle, differentiate, and migrate through the un-
derlying molecular layer to generate the internal granular layer of neu-
rons [6]. Oncogenic mutations leading to sustained Hh signaling in
CGNPs may override the usual signals regulating the fate of these cells,
resulting in their continued proliferation in medulloblastoma.
Bmi1 is a member of the Polycomb group of transcriptional repres-
sor proteins and regulates stem cell self-renewal, partially by repressing
the senescence and apoptosis-related genes p16Ink4a and p19Arf [7]. In
developing cerebellum, Bmi1 seems to be acting downstream of the
Hh pathway to control proliferation of CGNPs [4]. Thus, Bmi1-null
mice develop smaller cerebella secondary to impaired production of
granular neurons; however, overall cerebellar organization and cell
specification and differentiation seem relatively normal, although the
number of stellate cells in the molecular layer is reduced [4,8,9]. Bmi1
has also been implicated in Hh pathway–mediated self-renewal of
mammary stem cells and cancer stem cells [10]. BMI1 is aberrantly
expressed in a number of solid tumor types, including medulloblas-
toma [4], where BMI1 expression correlates with the activation of
the Hh pathway. Several studies suggest a role for Bmi1 in the mainte-
nance of cultured or grafted tumor cells [11–13], and a recent report
established a requirement for Bmi1 in K-ras–driven lung tumorigene-
sis in mice [14]. However, a requirement for Bmi1 in the spontaneous
development of medulloblastomas or other solid tumors arising in
the central nervous system has not been demonstrated. In this work,
we investigated the role of Bmi1 in the pathogenesis of Hh-driven
medulloblastoma, using a novel, fully penetrant mouse model expres-
sing the oncogenic Hh effector SmoA1 [3,15].
Figure 1. Bmi1 is required for Hh pathway–driven medulloblastoma expansion. (A) Hematoxylin and eosin staining of coronal sections
from cerebella of P21 mice. (a) Tumors or (b) ectopic foci of presumed abortive tumor cells (both outlined with dotted black line) are
evident external to the molecular (ML in c) in SmoA1;Bmi1+/+ and SmoA1;Bmi1−/− animals, respectively. Areas of higher magnification
are indicated by black boxes on low power images. (B) Schematic representation of the proposed model showing cellular compartments
in developing cerebellum and SmoA1-induced tumors. In transgenic mice expressing SmoA1, tumors arise within the EGL and undergo
progressive expansion, leading to death within 10 to 12 weeks. The presence of a small focus of tumor-like cells in a P18 SmoA1;Bmi1−/−
mouse (Figures W1 and W2), with ectopic cells observed in a similar location in P21 SmoA1;Bmi1−/− animals, argues that medulloblas-
toma formation is initiated in the absence of Bmi1, but subsequent tumor development is arrested. This is further supported by the pres-
ence of ectopic nests of neuronal cells within themolecular layer (Figure 3B) seen in other mousemodels of medulloblastoma and human
medulloblastoma but not normal cerebellum, in all SmoA1;Bmi1−/−mice examined at P18 and P21 (N = 5). (C) Comparison of total vol-
umes of medulloblastomas (SmoA1;Bmi1+/+) and ectopic cells/abortive tumors (SmoA1;Bmi1−/−) at P21 (N = 3). Error bars indicate
range; * indicates statistically significant difference (P = .0044).
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Materials and Methods
Generation of Transgenic Animals, Breeding, and Genotyping
We generated a double-transgenic mouse model of medulloblastoma
using an HA-tagged, oncogenic allele of Smoothened, SmoA1 [3,15],
under the control of the tetracycline responsive element (TRE). Before
beginning experimental crosses, TRE-SmoA1 mice were backcrossed to
C57/BL6 mice for at least five generations. When these mice were
crossed with GFAP-tTA mice [16] to produce GFAP-tTA;TRE-SmoA1-
HA bitransgenic mice (designated SmoA1 for the sake of simplicity),
SmoA1 was expressed in glial and progenitor cells throughout the
CNS and led to rapid development of medulloblastoma (Supple-
mentary Note and Figures W1–W4). Details on generation of TRE-
SmoA1HA mouse lines, breeding with GFAP-tTA and Bmi1 mutant
Figure 2. Cell death and cell cycle marker expression in SmoA1;Bmi1+/+ medulloblastomas and SmoA1;Bmi1−/− ectopic cells. (A)
Immunohistochemical staining for transgene, apoptosis, and proliferation in P21 mice, with outer edge of molecular layer, when visible,
outlined with dotted black line. (a) HA-tagged SmoA1 is detected in SmoA1 tumors and ectopic lesions in SmoA1;Bmi1−/−mice, as well
as scattered cells in the molecular layer and internal granular later, but not in control (Wild Type) cerebellum. (b) TUNEL staining reveals
apoptosis in both tumors and ectopic cells. (c) High proliferation rate of the tumors is evident from PCNA staining of most tumor cells,
whereas only a few cells stain in the lesions of SmoA1;Bmi1−/− mice. (B) Cell cycle marker expression in P21 mice, with outer edge of
molecular layer, when visible, outlined with dotted black line. (a) Tumors express high levels of Bmi1 in nearly every cell. Bmi1 is also
appreciable in cells of the molecular layer and internal granular layer of wild type cerebellum. No Bmi1 is detected in tissue from SmoA1;
Bmi1−/− mice. (b) p19Arf is expressed in ectopic cells, and essentially undetectable within medulloblastomas. Higher magnification
(inset) demonstrates nucleolar staining. (c) Cyclin D1 is broadly expressed in medulloblastomas, but is virtually absent from Bmi1-
deficient lesions. (C) Apoptosis (% TUNEL-positive cells) is significantly higher in SmoA1;Bmi1−/− lesions and proliferation (% PCNA-
positive cells) is significantly lower (D) (N = 3). Error bars indicate range; * indicates significant differences at P = .028 (TUNEL) and P =
7.5 × 10−6 (PCNA).
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mice, genotyping, and housing, are described in Supplementary Mate-
rials and Methods and Figure W5. Both GFAP-tTA and Bmi1 mutant
mice were maintained on a C57/BL6 background.
Immunohistochemistry, In Situ Hybridization,
and X-gal Staining
For immunohistochemistry and in situ hybridization, tissue was
fixed overnight in 10% neutral-buffered formalin and transferred
to 70% ethanol before embedding in paraffin for sectioning. Post-
fixation processing and paraffin embedding were performed by
Histoserv, Inc. (Bethesda, MD). To definitively confirm the absence
of tumor in SmoA1;Bmi1−/− mice, serial coronal sections were cut
through the entire rostral-caudal length of the cerebella. All sections
were cut at 5 μm thickness. Before immunostaining for HA, NeuN,
GFAP, Nestin, or PCNA, tissues were subjected to antigen retrieval
by boiling in sodium citrate buffer for 10 minutes. The antibodies
used comprised HA (3F10, 1:100; Roche, Indianapolis, IN), NeuN
(MAB372, 1:200; Millipore/Chemicon, Billerica, MA), GFAP (Ab-4,
1:200; Neomarkers/Thermo Fisher, Freemont, CA), Nestin (Rat-401,
1:4; Developmental Studies Hybridoma Bank, Iowa City, IA), PCNA
(PC10, 1:200; Neomarkers/Thermo Fisher), and TUNEL (ApopTag
In Situ Peroxidase Kit; Millipore/Chemicon). Images were obtained
on an Olympus BX51 microscope, using an Olympus DP71 digital
camera (Olympus, Center Valley, PA). For immunostaining of Bmi1,
Cyclin D1, and p19Arf, microwave antigen retrieval was performed
for 20 minutes. The following primary antibodies were used:
Bmi1 (mouse monoclonal F6, 1:50), Cyclin D1 (Sc-753, 1:100;
Santa Cruz Biotechnology, Santa Cruz, CA), and p19Arf (R562,
1:150; Abcam, Cambridge, MA). Antibodies were detected by perox-
idase staining using the Powervision system (Immunologic, Duiven,
the Netherlands) followed by visualization on a Zeiss Axiovert micro-
scope (Zeiss, Thornwood, NY). In situ hybridization is described in
Supplementary Materials and Methods.
For X-gal staining, tissue was fixed in 4% paraformaldehyde for
1 hour at 4°C. Tissues were stained with X-gal overnight at 37°C,
then postfixed in 10% NBF, and processed as previously mentioned,
with the exception of using nuclear fast red counterstaining.
Tissue Volume, PCNA, and TUNEL Measurements
Approximate tissue volumes of P21 SmoA1;Bmi1+/+ tumors and
SmoA1;Bmi1-/- abortive lesions were measured using serial coronal sec-
tions as described in Supplementary Materials and Methods. The per-
centage of PCNA- or TUNEL-positive cells was determined on
sections from P21 SmoA1;Bmi1+/+ and SmoA1;Bmi1−/− mice (N = 3
for each group), as described in Supplementary Materials and Methods.
Figure 3. Lineage marker expression in SmoA1;Bmi1+/+ medulloblastomas and SmoA1;Bmi1−/− ectopic cells. (A–C) Immunohisto-
chemical staining of tissue from P21 mice, with outer edge of molecular layer, when visible, outlined with dotted black line. (A) Intense
immunostaining for the glial marker GFAP is seen in the ectopic cells of SmoA1;Bmi1−/− mice. Weaker GFAP immunostaining can be
appreciated in cells scattered throughout the tumor of SmoA1 mice, and in the molecular layer in all mice. (B) Weak expression of the
neuronal marker NeuN is detected in scattered cells within medulloblastoma but not abortive tumors. In addition, strongly NeuN-positive
clusters, representing aberrant collections of neurons, are evident within the outer molecular layers of all SmoA1;Bmi1+/+ and five of
the six SmoA1;Bmi1−/− mice examined, but not control mice. NeuN-positive neurons are appreciable in the expected location in the
internal granular layer of all mice. (C) Expression of the stem and progenitor cell marker nestin is appreciable in SmoA1 tumors but is
largely undetectable in lesions in SmoA1;Bmi1−/− mice.
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Quantitative Real-time Reverse Transcription–Polymerase
Chain Reaction
Quantitative polymerase chain reaction was performed on the Roche
LightCycler 2.0, using the LightCycler FastStart DNA MasterPlus
SYBR Green I kit (Roche) as per the manufacturer’s instructions.
RNA was isolated from wild type cerebellum or the ventrolateral re-
gion of tumor-bearing cerebellum, the region of greatest tumor burden,
using the RNEasy kit (Qiagen, Valencia, CA). One microgram of total
RNAwas treated with DNAse I (Invitrogen, Carlsbad, CA) and reverse-
transcribed using SuperScript II (Invitrogen). Of the resulting cDNA,
1/20th was used per quantitative polymerase chain reaction. Target
gene expression was normalized to actin expression, and relative control
cerebellum gene expression levels were set to 1. Specific primer se-
quences forActin,Math1,N-Myc,CyclinD1, andCyclinD2 can be found
in Supplementary Materials and Methods.
Results and Discussion
SmoA1 mice developed tumors resembling medulloblastoma as
early as postnatal day 7 (P7), with 100% penetrance by P14. Early
tumors were first detected as an expansion of EGL in a small ventro-
lateral region of the cerebellum. By P21, when the EGL is no longer
detected in wild type animals, tumors frequently extended along the
entire rostral-caudal length of the cerebellum when examined in se-
rial coronal sections (Figure 1A). Tumor-bearing SmoA1 animals died
within 10 to 12 weeks. Bitransgenic mice from three independently
derived TRE-SmoA1HA lines developed medulloblastomas with
100% penetrance; the data reported in this study were generated using
line #140.
To generate SmoA1 mice on a Bmi1-deficient background, we
crossed Bmi1+/−mice with either GFAP-tTA or TRE-SmoA1HAmice,
and then crossed the resulting GFAP-tTA;Bmi1+/− and TRE-SmoA1-
HA;Bmi1+/− progeny (Figure W5). We obtained SmoA1 mice on wild
type (N = 80), Bmi1+/− (N = 17), and Bmi1−/− (N = 6) backgrounds.
In striking contrast to the complete tumor penetrance in SmoA1 wild
type and SmoA1;Bmi1+/− mice, none of the six SmoA1;Bmi1−/− mice
developed full-blown medulloblastomas when examined at P18 to
P26. One of two P18 SmoA1;Bmi1−/−mice contained both presumed
abortive tumor cells, as described below, and a small focus of cells with
some similarities to medulloblastoma, but with notable differences
(Table 1 and Figures W6 and W7). In the additional P18 SmoA1;
Bmi1−/− mouse and three P21 SmoA1;Bmi1−/− mice, tumors were
not detected. Instead, small ectopic foci of presumed abortive tumor
cells were identified external to the molecular layer (Figure 1A), a re-
gion normally devoid of cells at this stage (Figure 1A). These cells
were not detected at P26. The presence of tumor-like cells in a P18
SmoA1;Bmi1−/− mouse, populations of residual ectopic cells in P18
(N = 2) and P21 (N = 3) mice, and the absence of these cells at
P26 (N = 1) implies that medulloblastoma formation is initiated in
Bmi1−/− mice, but the subsequent expansion of tumors is blocked
and residual tumor cells are ultimately eliminated (Figure 1B). Our
findings suggest a more stringent requirement for Bmi1 in medullo-
blastoma development than in leukemia, which is blocked by Bmi1
deficiency in secondary but not primary recipients [17]. This may re-
flect differential requirements for Bmi1 in expansion of CGNPs versus
hematopoietic stem cells.
Compared to age-matched wild type medulloblastomas, ectopic
cells in P21 SmoA1;Bmi1−/− mice had a lower nuclear-to-cytoplasmic
ratio and pale eosinophilic cytoplasm, and the lesions occupied 1/
140th the volume (Figure 1C ): mean SmoA1;Bmi1+/+ tumor volume
was 2.69 mm3, whereas mean SmoA1;Bmi1−/− lesion volume was
0.019 mm3 (P = .0044). Medulloblastoma cells in wild type mice
and cells in ectopic foci in Bmi1−/− mice both expressed SmoA1
(Figure 2A), indicating that impaired tumor growth in Bmi1−/− mice
cannot be attributed to lack of transgene expression. Apoptotic cells
were 4.7-fold more abundant in ectopic cells than medulloblastoma
(29.61% vs 6.26%, respectively, P = .028; Figure 2, A and C ). Prolif-
eration was also impaired in SmoA1;Bmi1−/− lesions; PCNA-positive
cells were reduced 13.3-fold, from 81.93% in SmoA1;Bmi1+/+ tu-
mors to 6.18% in ectopic lesions (P = 7.5 × 10−6; Figure 2, A and D).
These data suggest that both increased apoptosis and reduced prolif-
eration contributed to the impaired outgrowth of putative medullo-
blastoma progenitors in the absence of Bmi1. Interestingly, a recent
report showed that Gli1 blocks proliferation and induces apoptosis
of cerebellar neural stem cells but not medulloblastoma stem cells
[18], raising the possibility that Bmi1may play a role in protecting these
tumor cells from Hh pathway–driven apoptosis.
We next examined Bmi1 protein and cell cycle marker expression
in Bmi1+/+ and Bmi1−/− lesions. SmoA1;Bmi1+/+ tumors expressed
Bmi1 in almost all cells, whereas no Bmi1 was detected in SmoA1;
Bmi1−/− animals (Figure 2B), as expected. Conversely, p19Arf was de-
tected in cells scattered throughout the ectopic foci in SmoA1;Bmi1−/−
cerebella, whereas it was weakly expressed in medulloblastomas
Table 1. Histologic Diagnosis and Immunophenotyping Summary of Cerebella from SmoA1-Expressing Wild Type and Bmi1−/− Mice.
Age SmoA1;Bmi1+/+ SmoA1;Bmi1−/−
P14 and older P18 (8940)* P18 (8941) P21 (8021, 132-3.2, 135-3.5) P26 (8221)
H&E, ectopic cells outside of molecular layer† Medulloblastoma Proliferative focus and abortive cells Abortive cells Abortive cells Normal
H&E, ectopic cell clusters within molecular layer‡ + + + + −
PCNA ++++ +++¶ + + NA#
Cyclin D1 ++++ +++ + + NA
Nestin +++ + − − NA
Nestin (large, round cells)§ − ++ ++ + −
NeuN + + − − NA
GFAP + ++ ++++ ++++ NA
p19 +/− + ++ ++ NA
*Numbers in parentheses are animal identifiers.
†Refers specifically to any unexpected cell populations outside the molecular layer.
‡Refers to ectopic clusters of neuron-like cells in outer region of the molecular layer, underneath tumor or abortive cells.
¶Immunohistochemistry for animal 8940 refers specifically to cells within the proliferative focus.
#NA indicate not analyzed, because abortive tumor cells were not detected at P26.
§At P18, these distinctive cells were detected both in ectopic regions and molecular layer (Figure W6); at P21, detected only in molecular layer.
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(Figure 2B). This observation is consistent with an inhibitory role
for p19Arf in CGNP proliferation and cerebellar development [8]
and suggests that Bmi1 blocks p19Arf expression in Hh-induced me-
dulloblastoma. Cyclin D1, a Hh target that acts downstream of
p16Ink4a [19], was weakly expressed in a small fraction of ectopic cells
in SmoA1;Bmi1−/−mice but was strongly expressed inmedulloblastomas
(Figure 2B). Given that Cyclin D1 is required for medulloblastoma
development [20], its loss in Bmi1-deficient, SmoA1-expressing cere-
bellum may contribute to the failure to form tumors. Up-regulation
of the CDK inhibitor p21 was not detected in Bmi1-deficient ectopic
lesions (not shown).
We also examined expression of lineage markers and the stem and
progenitor cell marker nestin. Compared to medulloblastomas, ec-
topic lesions in SmoA1;Bmi1−/− mice contained a predominance of
cells intensely positive for GFAP, but essentially no NeuN-positive
neuronal cells (Figure 3, A and B). This marker profile suggests that
ectopic cells in SmoA1;Bmi1−/− mice are distinct from the preneo-
plastic lesions described in PtchlacZ/+ mice [21]. Increased expression
of GFAP in residual cells raises the theoretical possibility that GFAP
promoter–driven SmoA1 may be accumulating to toxic levels in
some Bmi1-deficient cells, but additional studies would be required
to test this idea. In both SmoA1;Bmi1+/+ and SmoA1;Bmi1−/− mice,
clusters of postmitotic, strongly NeuN-positive neuronal cells were
detected in the outer molecular layer just deep to either tumors or
ectopic regions, respectively (Figure 3B). The presence of these mis-
placed cell aggregates, never detected in nontransgenic mice, is in
keeping with the idea that there is similar initial tumorigenic re-
sponse to SmoA1 in the EGL of Bmi1−/− (Figures W1 and W2 and
Table 1) and wild type mice, but it cannot be sustained in the absence
of Bmi1. We also observed a striking reduction in nestin-positive
cells in SmoA1;Bmi1−/− ectopic foci (Figure 3C ), indicating a depletion
of progenitor cells in these presumably abortive lesions. This loss of
progenitor-like cells likely contributes to the failure of nascent medul-
loblastomas to progressively expand in the absence of Bmi1.
In addition to our findings in P21 and P26 animals described, we
also examined SmoA1;Bmi1−/− mice at an earlier time point, as noted
above. Whereas one of two P18 SmoA1;Bmi1−/− mice was similar to
P21 mice, the other P18 SmoA1;Bmi1−/− mouse contained a small
focus of cells with properties intermediate between medulloblastomas
and ectopic foci seen in SmoA1;Bmi1−/− mice at P21. This interme-
diate lesion was much thinner than age-matched SmoA1;Bmi1+/+ me-
dulloblastoma (Figure W1A). Whereas the abortive SmoA1;Bmi1−/−
tumor-like lesion was proliferative, fewer cells stained for PCNA and
Cyclin D1 than in Bmi1+/+ tumor, and expression of p19Arf was el-
evated (Figure W1, B–D). Increased GFAP immunostaining was seen
at the periphery of this lesion as well (Figure W2A). In keeping with
what is seen at P21, there is a marked reduction in nestin staining
in the Bmi1-deficient lesion and an alteration in its subcellular dis-
tribution, including the appearance of large, round, nestin-positive
cells (Figure W2B). These distinctive cells, which are never seen in
wild type control or SmoA1;Bmi1+/+ mice, are detected both in re-
gions of ectopic cells and in the molecular layer of 18-day-old and, to
a lesser extent, 21-day-old animals, but are absent by postnatal day 26
(data not shown). Immunohistochemical data from all animals are
summarized in Table 1.
Although we cannot formally exclude the possibility that failure of
SmoA1;Bmi1−/− mice to develop full-blown medulloblastomas is
caused by a Bmi1-dependent loss of tumor progenitor cells, we do
not believe this to be the case. Bmi1 deficiency impairs Shh-driven
proliferation of CGNPs, the likely cell of origin for the medullo-
blastomas in our model. However, the cerebella of Bmi1−/− mice
develop relatively normally, despite their smaller size, with forma-
tion of the molecular, Purkinje, and internal granular layers, albeit
with abnormal basket neuron arborization and reduced molecular
layer cellularity [4]. Moreover, the presence of an intermediate tumor-
like lesion in a SmoA1;Bmi1−/−mouse at P18 and ectopic nests of Neu-
N-positive cells in five of six SmoA1;Bmi1−/− mice strongly argues that
tumor initiation can occur. Although a major effect of Bmi1 deficiency
thus seems to be at the level of medulloblastoma expansion/progression,
which is in keeping with Bmi1’s proposed role in lung tumorigenesis
[14], Bmi1 may also be involved in medulloblastoma initiation.
Taken together, our data establish an obligatory role for Bmi1 in
Hh-driven medulloblastoma pathogenesis, provide the first demon-
stration that Bmi1 is required for de novo development of a sponta-
neously arising solid tumor in the brain, and identify Bmi1 as a
critical downstream effector in tumorigenesis driven by uncontrolled
Hh pathway activation. Progression of SmoA1-expressing CGNPs to
medulloblastoma involves many of the same molecular pathways that
regulate physiologic CGNP proliferation and growth arrest, and loss
of Bmi1, by disrupting these signals, prevents expansion of Hh-
driven medulloblastomas. Further studies will be required to ascer-
tain whether Bmi1 is required for other pathological or physiological
responses to Hh signaling and to establish whether BMI1 will be a
useful target for the prevention or treatment of human malignancy.
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Supplementary Note
To examine Hh pathway activation in SmoA1-driven medulloblasto-
mas, we performed in situ hybridization for Hh pathway components
Ptch1 and Gli1 (Figure W1). Robust expression of both Ptch1 and
Gli1, indicating high-level activation of the pathway, was seen in tu-
mors. We also examined the expression of additional key genes by
quantitative real-time RT-PCR. Math1, a marker for EGL cells that
is seen in both mouse and human medulloblastomas [1,2], was up-
regulated approximately 550-fold in tumors (Figure W2A). N-Myc, a
Hh target gene critical to Hh-driven cerebellum development and
medulloblastoma formation [3], was up-regulated 17-fold in tumors
(Figure W2B), whereas the Hh targets CyclinD1 and CyclinD2 were
overexpressed 11- and 24-fold, respectively (Figure W2, C and D).
CyclinD1 is also required for medulloblastoma formation in Ptch1+/−
mice [4].
To assess the location and timing of transgene activation and early
tumor formation, we stained 2-day-old GFAP-tTA;TRE-lacZ mice
with X-gal. We observed scattered single or small groups of X-gal–
stained cells in the EGL of young mice (Figure W3). Consistent
with these data, we also observed SmoA1 expression in small clusters
of cells in the EGL of 7-day-old SmoA1mice (FigureW4, A and B). By
day 14, however, these small groups of cells had progressed to small
masses with robust expression of SmoA1 in 100% of mice examined
(Figure W4, C and D).
On the basis of lineage marker studies, Hh pathway activation
studies, and overall histologic appearance, the tumors arising in
SmoA1 mice resemble previously publishedmouse models of medullo-
blastoma and human medulloblastoma. In addition, SmoA1 mice de-
velop very large tumor burden and either die spontaneously or become
moribund and must be euthanized by 10 to 12 weeks, with only one
SmoA1 mouse surviving for 16 weeks.
Supplementary Materials and Methods
Generation of TRE-SmoA1 Mouse Lines
To generate TRE-SmoA1 mice, we appended a sequence encod-
ing an HA epitope tag to the 3′ end of SmoA1 and placed it under
transcriptional control of the tetracycline responsive element. We li-
gated the resulting construct into the multiple cloning site of the pTet-
Splice vector (Invitrogen), placing it under transcriptional control of
the tetracycline responsive element. Complete details of construct gen-
eration can be found elsewhere.1 We confirmed the identity of our
transgenic construct by sequencing the completed construct at the
University of Michigan Sequencing Core. Comparison of obtained
primary sequence data with RefSeq mRNA sequence (NM_176996.3)
confirmed the presence of the expected W539L mutation and also
revealed the presence of an unexpected second point mutation,
T425R. We excised and purified the TRE-SmoA1HA/SV40 Intron +
poly adenylation fragment, which was microinjected into (C57BL/6 ×
SJL)F1 × (C57BL/6 × SVJ)F1 eggs by the University of Michigan
Transgenic Animal Core. Three TRE-SmoA1HA mouse lines (#99,
#140, and #149) were generated and maintained by backcrossing
founder mice onto C57BL/6 breeders for at least five generations be-
fore experimental crosses.
Genotyping and Housing of Bmi1−/− and TRE-SmoA1 Mice
We generated SmoA1 mice on Bmi1+/− and Bmi1−/− backgrounds
by crossing GFAP-tTA and TRE-SmoA1HA mice separately with
Bmi1+/− mice [5] and then intercrossing the resulting GFAP-tTA;
Bmi1+/− and TRE-SmoA1HA;Bmi1+/− progeny (Figure W5). We
chose to use the GFAP promoter (in GFAP-tTA;TRE-SmoA1 mice)
because GFAP-Cre–driven deletion of Rb in a p53-deficient back-
ground yielded medulloblastomas [6]; the GFAP promoter targets
various progenitor cells as well as glia, allowing us to assess the con-
sequences of Hh pathway deregulation in several cell populations in
the CNS, in future studies; and a GFAP-tTA transgenic line had al-
ready been generated and characterized [7] and bitransgenic GFAP-
tTA;TRE-IFNγ mice reported to yield medulloblastomas with high
penetrance owing to the activation of endogenous Shh expression [8].
The rationale for a bitransgenic approach stems from the fact that
conventional transgenic mice expressing SmoA1, if they develop a ro-
bust tumor phenotype, might not be capable of surviving to breed to
generate lines. Pups were genotyped between P14 and P21, by which
point Bmi1−/− animals were readily distinguished by their smaller body
size. Bmi1, GFAP-tTA, and TRE-SmoA1HA genotypes were con-
firmed by PCR. Bmi1 genotype was confirmed by multiplex PCR
for both the hygromycin cassette in the Bmi1 knockout allele (5′-
cgccgtgcacagggtgtcacgttgcaagac-3′ and 5′-caagccaaccacggcctccagaag-
3′) [9] and the wild type Bmi1 allele (5′-ccaccacaacacctcatcac-3′ and
5′-cgggtgagctgcataaaaat-3′). SmoA1 genotype was ascertained by indi-
vidual PCR for the tetracycline transactivator for GFAP-tTA (5′-
ctcgcccagaagctaggtgt-3′ and 5′-ccatcgcgatgacttagt-3′ [10]) and the
SV40 poly-A tail for TRE-SmoA1HA (5′-ggaactgatgaatgggagca-3′
and 5′-gggaggtgtgggaggttt-3′). In total, 90 litters were screened, com-
prising 417 pups from 70 of the litters, and an additional 20 litters of
unrecorded size, which contained no Bmi1−/− pups by phenotype and
were therefore killed without further analysis.
Owing to impaired hematopoietic function and increased risk of
infection in Bmi1−/− mice, all animals were maintained on water
supplemented with 0.1214 mg/ml polymixin B sulfate (Sigma) and
1.1 mg/ml neomycin trisulfate (Sigma). Maintenance of mouse col-
onies and experimental procedures were approved by the University
of Michigan University Committee on the Use and Care of Animals.
In Situ Hybridization
Nonradioactive in situ hybridization for Ptch1 and Gli1 was per-
formed essentially as described in detail elsewhere [11].
Approximate Tissue Volume Measurements
Approximate tissue volumes were calculated using a previously
published protocol [4], with serial 5-μm-thick coronal sections cut
through the entire rostral-caudal length of P21 SmoA1;Bmi1+/+ and
SmoA1;Bmi1−/− cerebella (N = 3 for each group), and every third or
every fourth slide stained with hematoxylin and eosin (H&E). To
calculate the rostral-caudal extent of the lesions, we counted the total
number of sections over which the lesions extended, measured the
cross-sectional surface area on each H&E–stained section for an in-
dividual lesion using ImageJ software, and averaged these values to ob-
tain a mean cross-sectional lesion area. We multiplied this mean area
by the total rostral-caudal length of the lesion to calculate approximate
volume measurements. P values were obtained using 2-tailed t test, as-
suming unequal variances.
1Michael LE, Ferris JE, Wang A, Diener JM, Liu J, Ellison DW, and Dlugosz AA (in prepa-
ration). Spatial and temporal requirements for Hh signaling in medulloblastoma pathogenesis.
Calculating Percentage of PCNA- or TUNEL-positive Tumor
or Ectopic Cells
After immunostaining tissue sections from three SmoA1;Bmi1+/+
and three SmoA1;Bmi1−/− animals for PCNA or TUNEL as de-
scribed in the Materials and Methods section, we photographed 10
random nonoverlapping high-power fields of tumor or ectopic tissue
for each animal. If there were fewer than 10 high-power fields’worth of
cells in a given SmoA1;Bmi1−/− lesion, we photographed all ectopic
cells present in the section. We then counted both the number of
PCNA or TUNEL-positive nuclei per field and the total number of
nuclei per field, and divided the number of positive nuclei by the total
number of nuclei to obtain the percent positive nuclei. P values were
calculated using the 2-tailed t test, assuming unequal variances.
Quantitative Real-time RT-PCR Primer Sets
Quantitative polymerase chain reaction was performed as de-
scribed in the Materials and Methods section, using the following
primer sets:
Actin: 5′-tgttaccaactgggacgaca-3′ and 5′-tctcagctgtggtggtgaag-3′.
Math1: 5′-tgcgctcactcacaaataag-3′ and 5′-taacaacacaatagtccgtgttc-3′.
N-myc: 5′-gctgcggtcactagtgtgtc-3′ and 5′-ggagaagcctcgctcttgat-3′.
CyclinD1 [12]: 5′-ctctggctctgtgcctttct-3′ and 5′-ccggagactcagag-
caaact-3′.
CyclinD2 [12]: 5′-ttcagcaggatgatgaagtga-3′ and 5′-gagaaggggctag-
cagatga-3′.
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Figure W1. The Hh pathway is activated in SmoA1-induced medulloblastomas. (A) Hematoxylin and eosin staining of the cerebellum
from a 7-week-old SmoA1 mouse, demonstrating large tumor burden (T) outside the molecular layer (ML) and internal granular layer
(IGL). (B–C) In situ hybridization for Ptch1 (B) and Gli1 (C) in nearby sections, demonstrating robust activation of the Hh pathway in tumors.
Figure W2.Medulloblastoma markers and Hh target genes are overexpressed in medulloblastomas. (A–D) Quantitative real-time RT-PCR
reveals overexpression of Math1 (A; 550-fold overexpression, P = .0097), N-Myc (B; 17-fold overexpression, P = .012), CyclinD1 (C;
11-fold overexpression, P = .0026), and CyclinD2 (D; 24-fold overexpression, P = .00064) in tumor-bearing cerebellum compared to
control wild type cerebellum. N = 5 for each group; error bars indicate standard error of the mean; * indicates statistical significance.
Figure W3. X-gal staining of 2-day-old GFAP-tTA;TRE-lacZ mouse cerebella. Overnight X-gal staining of P2 control (A) and GFAP-tTA;TRE-
lacZ pups (B) revealed tTA activity in few cells scattered throughout the EGL at this stage. X-gal–stained cells in the EGL existed either
singly or in small groups of cells.
Figure W4. Immunostaining reveals focal SmoA1 expression in the mouse EGL at 7 and 14 days old. Detection of SmoA1 expression by
immunostaining for the HA epitope tag revealed small clusters of SmoA1-positive cells in the EGL of 7-day-old pups (A, B, arrow), with
only minor disruption of the normally smooth regular surface of the EGL. By 14 days old, whereas control EGL had begun to regress (C),
readily identifiable SmoA1-expressing masses were already appreciable (D).
Figure W5. Three-step breeding scheme to generate SmoA1;Bmi1−/− mice. (1) GFAP-tTA and (2) TRE-SmoA1 mice were independently
crossed with Bmi1+/−mice to generate GFAP-tTA;Bmi1+/− and TRE-SmoA1;Bmi1+/−mice, respectively. These progeny were then inter-
crossed (3) to generate GFAP-tTA;TRE-SmoA1;Bmi1−/− mice, designated SmoA1;Bmi1−/−. A predicted 1 of 16 newborn pups from the
final crosses (GFAP-tTA;Bmi1+/− × TRE-SmoA1;Bmi1+/−) express SmoA1 on a Bmi1 null background (GFAP-tTA;TRE-SmoA1;Bmi1−/−),
but in reality, the actual proportion of mice obtained with this genotype is much lower because of the impaired viability of Bmi1−/−mice.
Figure W6. Cell cycle marker differences between intermediate tumor-like focus in P18 SmoA1;Bmi1−/− cerebellum and full-blown
medulloblastoma in SmoA1;Bmi1+/+ mice. (A) Hematoxylin and eosin staining of medulloblastoma SmoA1;Bmi1+/+ and intermediate
lesion (SmoA1;Bmi1−/−). Histologic appearance of intermediate tumor-like lesion is similar to full-blown tumor, but the lesion is notably
smaller. Shown in this image is the ectopic region with the maximal cross-sectional area. (B) PCNA stains both tumor and intermediate
Bmi1−/− tumor-like focus, but stains fewer cells in the Bmi1-deficient lesion. Insets show higher magnification. Cyclin D1 expression is
lower (C) and p19Arf is elevated (D) in the SmoA1;Bmi1−/− lesion.
Figure W7. Increased glial density and loss of nestin expression in intermediate P18 SmoA1;Bmi1−/− tumor-like lesion. (A) Intense GFAP
staining is seen in the outer region of the P18 SmoA1;Bmi1−/− tumor-like lesion, similar to the pattern seen in the ectopic regions of P21
animals. (B) Marked reduction of nestin-positive cells and alteration of subcellular nestin distribution is appreciable in SmoA1;Bmi1−/−
mice at P18. Insets show higher magnification of tumor SmoA1;Bmi1+/+ or molecular layer (SmoA1;Bmi1−/−).
